Product: ASS1 Antibody
Catalog: BF0242
Description: Mouse monoclonal antibody to ASS1
Application: WB IHC ELISA
Reactivity: Human, Mouse, Monkey
Mol.Wt.: 47kDa; 47kD(Calculated).
Uniprot: P00966
RRID: AB_2833984

View similar products>>

   Size Price Inventory
 50ul $250 In stock
 100ul $350 In stock
 200ul $450 In stock

Lead Time: Same day delivery

For pricing and ordering contact:
Local distributors

Product Info

ELISA 1:10000, WB 1:500-1:2000, IHC 1:200-1:1000
*The optimal dilutions should be determined by the end user.

WB: For western blot detection of denatured protein samples. IHC: For immunohistochemical detection of paraffin sections (IHC-p) or frozen sections (IHC-f) of tissue samples. IF/ICC: For immunofluorescence detection of cell samples. ELISA(peptide): For ELISA detection of antigenic peptide.

Monoclonal [AFB1961]
ASS1 antibody detects endogenous levels of total ASS1.
Cite Format: Affinity Biosciences Cat# BF0242, RRID:AB_2833984.
Mouse IgG1 in phosphate buffered saline (without Mg2+ and Ca2+), pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol. Store at -20 °C. Stable for 12 months from date of receipt.


Argininosuccinate synthase 1; Argininosuccinate synthase; Argininosuccinate synthetase 1; ASS; Ass-1; ass1; ASSA; ASSY_HUMAN; Citrulline aspartate ligase; Citrulline--aspartate ligase; CTLN1;



Purified recombinant fragment of human ASS1 expressed in E. Coli.


Expressed in adult liver.

The protein encoded by this gene catalyzes the penultimate step of the arginine biosynthetic pathway. There are approximately 10 to 14 copies of this gene including the pseudogenes scattered across the human genome, among which the one located on chromosome 9 appears to be the only functional gene for argininosuccinate synthetase. Mutations in the chromosome 9 copy of ASS cause citrullinemia. Two transcript variants encoding the same protein have been found for this gene.

Research Backgrounds


One of the enzymes of the urea cycle, the metabolic pathway transforming neurotoxic amonia produced by protein catabolism into inocuous urea in the liver of ureotelic animals. Catalyzes the formation of arginosuccinate from aspartate, citrulline and ATP and together with ASL it is responsible for the biosynthesis of arginine in most body tissues.


Acetylated by CLOCK in a circadian manner which negatively regulates its enzyme activity. Deacetylated by histone deacetylases.

Subcellular Location:


Extracellular region or secreted Cytosol Plasma membrane Cytoskeleton Lysosome Endosome Peroxisome ER Golgi apparatus Nucleus Mitochondrion Manual annotation Automatic computational assertionSubcellular location
Tissue Specificity:

Expressed in adult liver.

Subunit Structure:

Homotetramer. Interacts with NMRAL1. Interacts with CLOCK; in a circadian manner.


Belongs to the argininosuccinate synthase family. Type 1 subfamily.

Research Fields

· Metabolism > Amino acid metabolism > Arginine biosynthesis.

· Metabolism > Amino acid metabolism > Alanine, aspartate and glutamate metabolism.

· Metabolism > Global and overview maps > Metabolic pathways.

· Metabolism > Global and overview maps > Biosynthesis of amino acids.


1). LAP3 contributes to IFN-γ-induced arginine depletion and malignant transformation of bovine mammary epithelial cells. BMC Cancer (PubMed: 35941558) [IF=3.8]

Application: WB    Species: Human    Sample: BMECs

Fig. 3LAP3 downregulates arginine level by interfering with ASS1 in BMECs. a-e Targeted metabolomics were performed to detect intracellular levels of citrulline (a), putrescine (b), agmatine (c), ornithine (d), and spermine (e) with IFN-γ or in combination with 100 mg/mL LAP3 inhibitor, bestatin. f Western blotting was used to detect the expression of ASS1 protein in LAP3 knocked-down BMECs upon IFN-γ treatment. Full-length blots are presented in Supplementary Fig. S7. g Western blotting showed the changes of ASS1 protein expression after treatment with LAP3 inhibitor bestatin in malignant transformed BMECs cells. Full-length blots are presented in Supplementary Fig. S8. h Determination of the change in arginine content of malignant BMECs treated with the LAP3 inhibitor, bestatin. The relative level of the target protein was estimated using densitometry and the ratio was calculated relative to the GAPDH control. Bars represent mean values with error bars to represent SD from three independent replicates. Differences between mean values were assessed by two-tailed Student’s t-test. *p < 0.05; **p < 0.01; ***p < 0.001, compared to control

Application: IHC    Species: Human    Sample: breast cancer cell

Fig. 8LAP3 was highly expressed in human breast cancer samples. a, c ELISA experiment was used to detected the protein expression levels of LAP3 (a) and ASS1 (c) in plasma of breast cancer patients and healthy control. Bars represent mean values with error bars to represent SD from three independent replicates. Differences between mean values were assessed by two-tailed Student’s t-test. *p < 0.05; **p < 0.01; ***p < 0.001, compared to control. b Representative images of IHC staining of LAP3 and ASS1. Scale bar, 200 μm

Restrictive clause


Affinity Biosciences tests all products strictly. Citations are provided as a resource for additional applications that have not been validated by Affinity Biosciences. Please choose the appropriate format for each application and consult Materials and Methods sections for additional details about the use of any product in these publications.

For Research Use Only.
Not for use in diagnostic or therapeutic procedures. Not for resale. Not for distribution without written consent. Affinity Biosciences will not be held responsible for patent infringement or other violations that may occur with the use of our products. Affinity Biosciences, Affinity Biosciences Logo and all other trademarks are the property of Affinity Biosciences LTD.